Literature DB >> 16258237

Antibody engineering for the development of therapeutic antibodies.

Sang Jick Kim1, Youngwoo Park, Hyo Jeong Hong.   

Abstract

Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical industry. There are currently 19 monoclonal antibodies in the market that have been approved by the FDA and over 150 in clinical developments. Driven by innovation and technological developments, therapeutic antibodies are the second largest biopharmaceutical product category after vaccines. Antibodies have been engineered by a variety of methods to suit a particular therapeutic use. This review describes the structural and functional characteristics of antibody and the antibody engineering for the generation and optimization of therapeutic antibodies.

Mesh：

Substances：

Year:  2005        PMID： 16258237

Source DB:  PubMed          Journal:  Mol Cells        ISSN： 1016-8478            Impact factor:   5.034


  23 in total

1.  Specific targeting of hepatitis C virus core protein by an intracellular single-chain antibody of human origin.

Authors:  Juliane Karthe; Kathi Tessmann; Jisu Li; Raiki Machida; Maaike Daleman; Dieter Häussinger; Tobias Heintges
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

Review 2.  Antibody-cytokine fusion proteins: applications in cancer therapy.

Authors:  Elizabeth Ortiz-Sánchez; Gustavo Helguera; Tracy R Daniels; Manuel L Penichet
Journal:  Expert Opin Biol Ther       Date:  2008-05       Impact factor: 4.388

Review 3.  Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies.

Authors:  Carmel M Lynch; Bruce W Hart; Iqbal S Grewal
Journal:  MAbs       Date:  2009 Jan-Feb       Impact factor: 5.857

4.  MoFvAb: Modeling the Fv region of antibodies.

Authors:  Alexander Bujotzek; Angelika Fuchs; Changtao Qu; Jörg Benz; Stefan Klostermann; Iris Antes; Guy Georges
Journal:  MAbs       Date:  2015       Impact factor: 5.857

5.  Targeting Colorectal Cancer Cell Lines Using Nanobodies; AgSK1as a Potential Target.

Authors:  Seyed Khalil Rashidi; Seyed Latif Mousavi Gargari; Walead Ebrahimizadeh
Journal:  Iran J Biotechnol       Date:  2017-08-19       Impact factor: 1.671

6.  Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha.

Authors:  Weibo Cai; Zachary J Kerner; Hao Hong; Jiangtao Sun
Journal:  Biochem Insights       Date:  2008-07-22

7.  Bispecific antibody complex pre-targeted delivery of polymer-drug conjugates for cancer therapy.

Authors:  Keyur S Gada; Vishwesh Patil; Rajiv Panwar; Arash Hatefi; Ban-An Khaw
Journal:  Drug Deliv Transl Res       Date:  2012-02       Impact factor: 4.617

8.  Targeted small interfering RNA-immunoliposomes as a promising therapeutic agent against highly pathogenic Avian Influenza A (H5N1) virus infection.

Authors:  Kannika Khantasup; Phikulthong Kopermsub; Kridsada Chaichoun; Tararaj Dharakul
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

9.  Human TNF cytokine neutralization with a vNAR from Heterodontus francisci shark: a potential therapeutic use.

Authors:  Tanya Camacho-Villegas; Teresa Mata-Gonzalez; Jorge Paniagua-Solis; Edna Sanchez; Alexei Licea
Journal:  MAbs       Date:  2012-12-05       Impact factor: 5.857

10.  Engineering and characterization of the chimeric antibody that targets the C-terminal telopeptide of the α2 chain of human collagen I: a next step in the quest to reduce localized fibrosis.

Authors:  Jolanta Fertala; Andrzej Steplewski; James Kostas; Pedro Beredjiklian; Gerard Williams; William Arnold; Joseph Abboud; Anshul Bhardwaj; Cheryl Hou; Andrzej Fertala
Journal:  Connect Tissue Res       Date:  2013-04-15       Impact factor: 3.417
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.